Search

everythinglearnresearchcommunity

for

Search:↓

Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

IL-9 increases skin cell movement but decreases their ability to invade, and this effect is controlled by cell contractility, not by MMPs.

A new therapy for a skin blistering condition has not been developed yet.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Curcumin applied to the skin can start hair growth in mice.

Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.

KIT's role in skin cells is not entirely independent, as other cells can influence its function.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.

Overexpressing 14-3-3σ in mice skin reduces cell growth and hair density.

New cytokine-targeted therapies show promise for treating alopecia areata.

The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.

Using the drugs AMD3100 and Tacrolimus together greatly improves skin healing and hair growth after a deep skin cut by increasing stem cells in the wound.

Targeting non-Smad pathways in TGF-β signaling may improve keloid treatment.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

Mice with extra PKCδ resist chemical-induced skin cancer but not UV-induced.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

TAT-GILZ peptide promotes hair growth by boosting stem cell activity.

Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.

Activating mitophagy may help manage a key immune response involved in the hair loss condition alopecia areata.

Researchers developed a scaffold that releases a healing drug over time, improving wound healing and skin regeneration.